Associations with PFS
| Variables of interest . | Total n (%) . | Median PFS (days) . | PFS 95% CI (days) . | Log-rank P value . |
|---|---|---|---|---|
| Bridging therapy | ||||
| Yes | 19 (70%) | 342 | 116-NA | .35*/.68†/.46‡ |
| No | 8 (30%) | 444 | 172-NA | |
| Bridging therapy response | ||||
| CR/PR | 11 (58%) | 342 | 164-NA | .76*/.68†/.75‡ |
| SD/PD | 8 (42%) | 129 | 116-NA | |
| CAR-T expansion | ||||
| Peak | ||||
| Low (≤28 777 copies/μg DNA) | 14 (58%) | 352 | 58-NA | .35*/.79†/.62‡ |
| High (>28 777 copies/μg DNA)) | 10 (42%) | 396 | 172-NA | |
| AUC (days 0-42) | ||||
| Low (≤281 copies/μg DNA × time) | 8 (33%) | 94 | 55-NA | .23*/.63†/.36‡ |
| High (>281 copies/μg DNA × time) | 16 (67%) | 396 | 172-NA | |
| AUC (days 14-42) | ||||
| Low (≤195 copies/μg DNA × time) | 12 (50%) | 94 | 55-NA | .19*/.71†/.25‡ |
| High (>195 copies/μg DNA × time) | 12 (50%) | 396 | 172-NA | |
| CD3+PD1+ % (PB) | ||||
| Pre-CD3.CAR-T | ||||
| Low (≤12%) | 8 (38%) | 352 | 164-NA | .97*/.93† |
| High (>12%) | 13 (62%) | 172 | 116-NA | |
| 2 wk after CD30.CAR-T | ||||
| Low (≤32%) | 12 (57%) | 374 | 116-NA | .83*/.92† |
| High (>32%) | 9 (43%) | 172 | 116-NA | |
| 4 wk after CD30.CAR-T | ||||
| Low (≤14%) | 8 (38%) | 535 | 352-NA | .32*/.13† |
| High (>14%) | 13 (62%) | 129 | 53-NA | |
| 6 wk after CD30.CAR-T | ||||
| Low (≤14%) | 10 (53%) | 444 | 129-NA | .31*/.28† |
| High (>14%) | 9 (47%) | 342 | 116-NA | |
| AUC (days 0-42) | ||||
| Low (≤7% × time) | 12 (57%) | 535 | 164-NA | .16*/.14† |
| High (>17% × time) | 9 (43%) | 129 | 116-NA | |
| AUC (days 14-42) | ||||
| Low (≤12% × time) | 9 (43%) | 535 | 164-NA | .43*/.36† |
| High (>12% × time) | 12 (57%) | 150 | 150-NA | |
| Metabolic tumor volume | ||||
| Pre-CAR-T (twofold method) | ||||
| Low (≤23 mL) | 12 (44%) | 535 | 342-NA | .07*/.03†/.09‡ |
| High (>23 mL) | 15 (56%) | 164 | 53-NA | |
| Pre-CAR-T (cutoff 60 mL) | ||||
| Low (≤60 mL) | 20 (74%) | 535 | 342-NA | .02*/.01†/.006‡ |
| High (>60 mL) | 7 (26%) | 129 | 42-NA | |
| Variables of interest . | Total n (%) . | Median PFS (days) . | PFS 95% CI (days) . | Log-rank P value . |
|---|---|---|---|---|
| Bridging therapy | ||||
| Yes | 19 (70%) | 342 | 116-NA | .35*/.68†/.46‡ |
| No | 8 (30%) | 444 | 172-NA | |
| Bridging therapy response | ||||
| CR/PR | 11 (58%) | 342 | 164-NA | .76*/.68†/.75‡ |
| SD/PD | 8 (42%) | 129 | 116-NA | |
| CAR-T expansion | ||||
| Peak | ||||
| Low (≤28 777 copies/μg DNA) | 14 (58%) | 352 | 58-NA | .35*/.79†/.62‡ |
| High (>28 777 copies/μg DNA)) | 10 (42%) | 396 | 172-NA | |
| AUC (days 0-42) | ||||
| Low (≤281 copies/μg DNA × time) | 8 (33%) | 94 | 55-NA | .23*/.63†/.36‡ |
| High (>281 copies/μg DNA × time) | 16 (67%) | 396 | 172-NA | |
| AUC (days 14-42) | ||||
| Low (≤195 copies/μg DNA × time) | 12 (50%) | 94 | 55-NA | .19*/.71†/.25‡ |
| High (>195 copies/μg DNA × time) | 12 (50%) | 396 | 172-NA | |
| CD3+PD1+ % (PB) | ||||
| Pre-CD3.CAR-T | ||||
| Low (≤12%) | 8 (38%) | 352 | 164-NA | .97*/.93† |
| High (>12%) | 13 (62%) | 172 | 116-NA | |
| 2 wk after CD30.CAR-T | ||||
| Low (≤32%) | 12 (57%) | 374 | 116-NA | .83*/.92† |
| High (>32%) | 9 (43%) | 172 | 116-NA | |
| 4 wk after CD30.CAR-T | ||||
| Low (≤14%) | 8 (38%) | 535 | 352-NA | .32*/.13† |
| High (>14%) | 13 (62%) | 129 | 53-NA | |
| 6 wk after CD30.CAR-T | ||||
| Low (≤14%) | 10 (53%) | 444 | 129-NA | .31*/.28† |
| High (>14%) | 9 (47%) | 342 | 116-NA | |
| AUC (days 0-42) | ||||
| Low (≤7% × time) | 12 (57%) | 535 | 164-NA | .16*/.14† |
| High (>17% × time) | 9 (43%) | 129 | 116-NA | |
| AUC (days 14-42) | ||||
| Low (≤12% × time) | 9 (43%) | 535 | 164-NA | .43*/.36† |
| High (>12% × time) | 12 (57%) | 150 | 150-NA | |
| Metabolic tumor volume | ||||
| Pre-CAR-T (twofold method) | ||||
| Low (≤23 mL) | 12 (44%) | 535 | 342-NA | .07*/.03†/.09‡ |
| High (>23 mL) | 15 (56%) | 164 | 53-NA | |
| Pre-CAR-T (cutoff 60 mL) | ||||
| Low (≤60 mL) | 20 (74%) | 535 | 342-NA | .02*/.01†/.006‡ |
| High (>60 mL) | 7 (26%) | 129 | 42-NA | |